Somatostatin Analogs Market Report 2026

Somatostatin Analogs Market Overview

• Somatostatin Analogs market size has reached to $7.16 billion in 2025 • Expected to grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Growing Aging Population Boost Somatostatin Analogs Market • Market Trend: Enhancing Precision Medicine With Advanced Somatostatin Analogs • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Somatostatin Analogs Market?

A somatostatin analog is a synthetic version of somatostatin that slows the production of hormones, such as serotonin and the growth hormone. It is used to reduce carcinoid syndrome symptoms, including diarrhea and skin flushing. The main types of somatostatin analogs are octreotide, lanreotide, and pasireotide. Octreotide refers to a medication that blocks growth hormones like the naturally occurring somatostatin, which is used to treat certain forms of tumor-related diarrhea and flushing. These are used in acromegaly, Cushing’s syndrome, neuroendocrine tumors, carcinoid syndrome, and others, used by end users including hospitals and pharmaceutical companies.

What Is The Somatostatin Analogs Market Growth Forecast?

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $10.15 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to biosimilar launches, expanded indications, aging population growth, improved diagnosis rates, specialty drug reimbursement. Major trends in the forecast period include growth of long-acting injectables, expanded neuroendocrine tumor indications, improved patient compliance focus, biosimilar development, hospital-based therapy growth.

Global Somatostatin Analogs Market Segmentation

1) By Type: Octreotide, Lanreotide, Pasireotide 2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments 3) By End User: Hospital, Pharmaceutical Companies Subsegments: 1) By Octreotide: Long-Acting Release (LAR) Formulations, Short-Acting Formulations 2) By Lanreotide: Depot Formulations, Injectable Formulations 3) By Pasireotide: Long-Acting Injectable Formulations, Subcutaneous Formulations

What Is The Driver Of The Somatostatin Analogs Market?

The growing aging population market is expected to propel the growth of the somatostatin analogs market going forward. The aging population refers to a demographic shift characterized by a higher proportion or an increasing number of individuals in a society who are aged 65 years and older. The rise in the aging demographic correlates with a higher incidence of diseases that warrant the use of Somatostatin Analogs, driving the demand for these pharmaceuticals. For instance, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, in 2022, there were 12.7 million people aged 65 or older in the UK, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, accounting for 27% of the population. Therefore, the growing aging population is driving the growth of the somatostatin analogs industry.

Key Players In The Global Somatostatin Analogs Market

Major companies operating in the somatostatin analogs market are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH

Global Somatostatin Analogs Market Trends and Insights

Major companies operating in the somatostatin analogs market are focused on developing advanced products, such as targeted radiopharmaceuticals, to enhance the precision and effectiveness of cancer treatments, specifically for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to bind specifically to cancer cells, allowing for precise delivery of therapeutic radiation to tumor sites while minimizing exposure to surrounding healthy tissues. For instance, in January 2024, Lantheus, a US-based radiopharmaceutical-focused company, launched Lutetium Lu 177 Dotatate. Lutetium Lu-177 Dotatate is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have demonstrated that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it a vital option for patients whose disease has progressed despite prior treatments. Its targeted approach allows for effective tumor control while minimizing systemic exposure, enhancing the overall therapeutic profile in managing neuroendocrine malignancies.

What Are Latest Mergers And Acquisitions In The Somatostatin Analogs Market?

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company collaborated with Philogen S.p.A. to enhance its portfolio, expand access to innovative cancer treatments. Through this collaboration, Sun Pharmaceutical aims to enhance its portfolio, expand access to innovative cancer treatments, and commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company focused on developing targeted therapeutics for oncology.

Regional Outlook

North America was the largest region in the global somatostatin analogs treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Somatostatin Analogs Market?

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Somatostatin Analogs Market Report 2026?

The somatostatin analogs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.